(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine

We are (NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine CAS:61747-22-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine
CAS.NO:61747-22-6
Synonyms:(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine
5-methoxy-4'-trifluoromethylvalerophenone oxime
 
Physical and Chemical Properties:
Density 1.17
Boiling Point 338ºC
Molecular Formula C13H16F3NO2
Molecular Weight 275.26700
Flash Point 158ºC
 
Specification:
Appearance:White powder
Assay:≥98.0%
Residue on ignition:≤0.1%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Fluvoxamine maleate(CAS:61718-82-9).

(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine


Related News: Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.2-isopropil-4-metil tiazol CAS:15679-13-7 We manufacture APIs and drug manufacturers make medicines from APIs.6,6-dimetil-3-azabiciclo [3.1.0] hexano CAS:943516-54-9 We manufacture APIs and drug manufacturers make medicines from APIs.1-(2-amino-4-methoxy-3-methylphenyl)ethanone “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Related Products
Product Name
2-Hydroxy-3-methoxy-3,3-diphenylpropanoic acid View Details
2,5-Dimethylfuran View Details
Fumaric Acid Monomethyl Ester View Details
2,6-Difluoro-4-hydroxybenzonitrile manufacturer 9-Bromo-10-(2-naphthyl)anthracene manufacturer 4-Hydroxypyridine-3-sulfonic acid manufacturer 3-methylpyridine-2-carbonitrile manufacturer 2-(tert-Butylamino)acetic acid hydrochloride manufacturer